Clinical Trial Update: Brivaracetam as add-on Treatment of Unverricht-Lundborg Disease in Adolescents and Adults [Phase 3]

View source ↗

Summary

A Phase 3 trial evaluating brivaracetam as add-on therapy for Unverricht-Lundborg disease in adolescents and adults has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Unverricht-lundborg Disease

Drugs mentioned

• Brivaracetam (Briviact) (brivaracetam)

Snippet

Sponsor: UCB Pharma SA | Conditions: Unverricht-Lundborg Disease | Phase 3 | Status: COMPLETED